Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker
A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study ...
Nov 26, 2014
0
2